Alterations in Mitochondrial Function in Pulmonary Vascular Diseases
Samar Farha, Kewal Asosingh, Paul M. Hassoun, John Barnard, Suzy Comhair, Andrew Reichard, Nicholas Wanner, Milena Radeva, Micheala A. Aldred, Gerald J. Beck, Erika Berman-Rosenzweig, Barry A. Borlaug, J. Emanuel Finet, Robert P. Frantz, Gabriele Grunig, Anna R. Hemnes

TL;DR
The study finds that mitochondrial function is altered in all types of pulmonary hypertension, with unique changes in a specific group linked to survival outcomes.
Contribution
The study identifies a unique mitochondrial phenotype in group 1 PAH associated with fatty acid metabolism and survival.
Findings
Global arginine bioavailability is consistently lower in all PH groups compared to controls.
Mitochondrial superoxide is higher in group 1 PAH and lowest in group 3.
Lower transmembrane potential in group 1 PAH is associated with transplant-free survival.
Abstract
Alterations of mitochondrial bioenergetics and arginine metabolism are universally present and mechanistically linked to pulmonary arterial hypertension (PAH), but there is little knowledge of arginine metabolism and mitochondrial functions across the different pulmonary hypertension (PH) groups. We hypothesize that abnormalities in mitochondrial functions are present across all PH groups and associated with clinical phenotypes. We test the hypothesis in PH patients and healthy controls from the Pulmonary Vascular Disease Phenomics Program cohort, who had comprehensive clinical phenotyping and follow-up for at least 4 years for death or transplant status. Mitochondrial transmembrane potential, superoxide production, and mass were measured by flow cytometry in fresh platelets. Metabolomics analysis was performed on plasma samples. Global arginine bioavailability was calculated as the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPulmonary Hypertension Research and Treatments · Cardiovascular Function and Risk Factors · Transplantation: Methods and Outcomes
